Two Sigma Investments
BTAI icon

Two Sigma Investments’s BioXcel Therapeutics BTAI Stock Holding History

Two Sigma Investments’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-27,029
Closed -$1.09M – 3158
2023
Q3 		$1.09M Buy
+27,029
New +$2.73M ﹤0.01% 1879
2023
Q2 		– Sell
-13,624
Closed -$4.07M – 3026
2023
Q1 		$4.07M Buy
+13,624
New +$5.82M 0.01% 1011
2022
Q4 		– Sell
-3,531
Closed -$668K – 2816
2022
Q3 		$668K Sell
3,531
-5,236
-60% -$1.22M ﹤0.01% 1643
2022
Q2 		$1.85M Buy
8,767
+3,800
+77% +$799K 0.01% 1245
2022
Q1 		$1.66M Buy
4,967
+2,914
+142% +$845K ﹤0.01% 1446
2021
Q4 		$668K Sell
2,053
-1,148
-36% -$493K ﹤0.01% 2948
2021
Q3 		$1.55M Sell
3,201
-4,984
-61% -$2.19M ﹤0.01% 2213
2021
Q2 		$3.81M Sell
8,185
-1,148
-12% -$626K 0.01% 1371
2021
Q1 		$6.45M Buy
+9,333
New +$7.51M 0.02% 915
2020
Q4 		– Sell
-1,075
Closed -$746K – 3352
2020
Q3 		$746K Sell
1,075
-3,175
-75% -$2.38M ﹤0.01% 1963
2020
Q2 		$3.6M Buy
+4,250
New +$2.77M 0.02% 805

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Investments's BTAI Position: Q4 2023 in Review

Two Sigma Investments sold out of BioXcel Therapeutics (BTAI) in Q4 2023, closing a stake of 27,029 shares — an estimated $1.09M sold.

Two Sigma Investments first reported a position in BTAI in Q2 2020 and held it in 11 quarters. The position peaked at $6.45M in Q1 2021. 73 funds tracked by Wall St. Rank hold BTAI as of Q4 2023.

  • Two Sigma Investments reported no remaining BioXcel Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Two Sigma Investments sold 27,029 BioXcel Therapeutics shares in Q4 2023, an estimated $1.09M.
  • Two Sigma Investments first reported a position in BioXcel Therapeutics in Q2 2020 and held it in 11 quarters.
  • Two Sigma Investments's BioXcel Therapeutics position peaked at $6.45M in Q1 2021.
  • 73 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2023.

Based on Two Sigma Investments's 13F filing for Q4 2023, filed 14 Feb 2024.